The short answer
NCI's prostate PDQ says the optimal follow-up strategy is uncertain and that a rising PSA alone may not be enough to start treatment. PSMA PET performs very differently by situation — 40% sensitivity for staging nodes, 95.8% for recurrence. Intermittent hormone therapy proved noninferior to continuous in a 1,386-man trial, in men whose PSA rose after radiation.
PDQ states the optimal follow-up strategy after prostate cancer treatment is uncertain, and that classifying men as indolent or progressing was poor at all examined PSA cut points.
After radical prostatectomy, PDQ says biochemical failure from an elevated or slowly rising PSA alone may not be sufficient to initiate additional treatment.
PSMA PET numbers depend entirely on the question: 40% sensitivity for staging pelvic nodes, but 95.8% sensitivity and 81.9% positive predictive value for 18F-piflufolastat in the setting of a rising PSA.
In a 1,386-man randomized trial of men with a rising PSA more than a year after radiation, intermittent androgen deprivation was noninferior to continuous, with median survival of 8.8 versus 9.1 years and a median 15.4 versus 43.9 months on treatment.
On this page
Choose how you want to read this
The whole article, with every detail and caution.
This page is for men whose PSA is rising after prostate cancer treatment, or whose cancer has come back, and for their families. It explains what NCI's PDQ summary says about PSA, scans, and hormone therapy choices.
What PDQ says about follow-up, before anything else
NCI's PDQ summary for health professionals begins its follow-up section with an admission. The optimal follow-up strategy for men treated for prostate cancer is uncertain.
It goes further. Using surrogate endpoints to make clinical decisions is controversial. A surrogate endpoint is a test result, like PSA, used as a stand-in for outcomes such as how long people live. And PDQ says the evidence that changing therapy on those endpoints brings clinical benefit is weak.
PSA is the surrogate in question. PDQ says the PSA test is used almost universally to follow patients. But it says the range of follow-up recommendations reflects a lack of research evidence behind them. A systematic review of international guidelines, it notes, highlighted the need for robust primary research.
One line is sharper still. PDQ reports that the accuracy of sorting men into groups whose cancer stayed indolent (slow and harmless) versus progressed was poor at all examined cut points of PSA or of PSA rate of change.
A rising PSA after surgery is not automatically a reason to treat
PDQ describes what a detectable PSA means after surgery. Then it qualifies it at once.
A detectable PSA level marks patients at higher risk of local treatment failure or spread. But a substantial share of patients with an elevated or rising PSA after surgery stay free of symptoms for long stretches.
PDQ draws the conclusion out loud. Biochemical evidence of failure, on the basis of an elevated or slowly rising PSA alone, may not be sufficient to initiate additional treatment.
It cites a look-back analysis of nearly 2,000 men. All had radical prostatectomy with curative intent. They were followed for a mean of 5.3 years. Of those, 315 men, or 15%, showed an abnormal PSA.
Where doubling time earns its place
Rate of change carries more weight in PDQ than absolute level does, but only within limits.
PDQ cites early data from a look-back cohort of 8,669 patients with localized prostate cancer. All had radical prostatectomy or radiation. A short PSA doubling time after treatment met some criteria as a surrogate endpoint. That study defined short as under 3 months. The endpoints were all-cause mortality and prostate cancer-specific mortality.
PDQ attaches two cautions. These findings need independent confirmation in prospective studies, and may not apply to patients on hormone therapy. It also notes there are no standard criteria for surrogacy, and no standard cut points, even in prospective trials.
So a doubling time is a real number to ask for. It is not a threshold that decides treatment on its own.
PSMA PET: what the numbers actually show
Prostate-specific membrane antigen, or PSMA, is a receptor expressed at high levels in prostate cancer. PDQ names two tracers used to image it: 68Ga-gozetotide and 18F-piflufolastat.
The figures differ sharply by what the scan is being asked to do.
For staging lymph nodes before treatment, a phase III trial enrolled 764 patients. It found 68Ga-gozetotide PET-CT had a sensitivity of 40% and a specificity of 95%. Sensitivity is how often a scan finds cancer that is there. Specificity is how often it correctly shows no cancer when there is none. The comparison was against pelvic lymph node dissection. The other tracer, 18F-piflufolastat, did much the same there. Its sensitivity was 40% and its specificity 98%.
For finding spread in high-risk disease, 68Ga-gozetotide PET-CT beat conventional imaging clearly. Sensitivity was 85% against 38%. Specificity was 98% against 91%.
For recurrence, which is what this page is about, the numbers improve again. PDQ says 68Ga-gozetotide PET-CT showed a high positive predictive value and detection rate there. It also did better than 18F-fluciclovine in that setting. For 18F-piflufolastat with a rising PSA, sensitivity was 95.8% and positive predictive value 81.9%.
A sensitivity of 40% for nodes before surgery and 95.8% for recurrence are very different things. Asking which of those situations a proposed scan belongs to is worth doing. These figures come from the National Cancer Institute’s “Prostate Cancer Treatment.”
Intermittent hormone therapy: the trial in full
This is the best-evidenced choice on the page, and the details are specific enough to use.
PDQ describes a randomized noninferiority trial in 1,386 men. A noninferiority trial tests whether a new approach is no worse than the standard one. All had a rising PSA above 3 ng/mL and serum testosterone above 5 nmol/L. All were more than a year past primary or salvage radiation for localized disease.
The intermittent arm used 8-month treatment cycles of an LH-RH agonist, combined with a nonsteroidal antiandrogen for at least the first 4 weeks. Treatment restarted whenever PSA rose above 10 ng/mL.
After a median follow-up of 6.9 years, with a maximum of 11.2 years, survival was nearly identical. Median survival was 8.8 years with intermittent therapy and 9.1 years with continuous. The hazard ratio for death was 1.02, with a 95% confidence interval of 0.86 to 1.21. That met the prospective criterion for noninferiority.
Prostate cancer-specific mortality was also similar, at a hazard ratio of 1.18, with a P value of .24.
The difference showed up in time on treatment and in quality of life. Men in the intermittent arm received a median of 15.4 months of treatment, against 43.9 months in the continuous arm. Intermittent therapy scored significantly better on three measures:
- Hot flashes
- Desire for sexual activity
- Urinary symptoms
Two context figures from that trial deserve repeating. Of all deaths, 59% were unrelated to prostate cancer, and 14% of all patients died of prostate cancer.
PDQ adds a systematic review of 15 randomized trials comparing continuous with intermittent therapy. It found no significant difference in three measures:
- Overall survival
- Prostate cancer-specific survival
- Time before the cancer grew
The review met the noninferiority criterion. But PDQ notes that all but one of those 15 trials carried an unclear or high risk of bias.
The question the intermittent trial did not answer
PDQ states this limit plainly, and it is the question people most often want answered.
That trial did not address whether starting any hormone therapy for an elevated PSA after initial local treatment extends survival, compared with waiting until symptoms appear.
A separate trial compared immediate against deferred androgen deprivation. At a median follow-up of 7.8 years, about half the deferred group had started treatment. Median overall survival was 7.4 years with immediate treatment. It was 6.5 years with deferred. The hazard ratio was 1.25, with a confidence interval of 1.05 to 1.48. PDQ says that failed to meet the criteria for noninferiority.
When to get help sooner
Prostate cancer that returns most often goes to bone. That is where the urgent signs come from.
- Call 911 or go to an emergency department if you have new back pain together with weakness, numbness, or pins and needles in your legs, trouble walking, or a loss of control over your bladder or bowel. That combination can mean the cancer is pressing on the spinal cord. Do not drive yourself.
- Call 911 or go to an emergency department if you cannot pass urine at all despite needing to. Do not drive yourself.
- Call your care team right away if back or hip pain is severe or worse at night. The American Cancer Society notes bone pain from spread tends to be worse at night.
- Call your care team right away if a bone gives sudden pain after a minor knock or a fall. Bone metastases and some hormone therapies weaken bone.
- Call your care team within a day or two if the flow of urine slows or stops starting, you are passing blood in urine, or hot flashes and other hormone therapy effects have become hard to live with.
Where to read next
The disease itself is described in prostate cancer. The general shape of a return workup is in when cancer comes back. The distinction between a local and a distant return is drawn in local vs. distant recurrence.
Sources
Common questions
Is there a standard follow-up schedule after prostate cancer treatment?
PDQ says the optimal follow-up strategy is uncertain. It notes the PSA test is used almost universally, but that the diversity of follow-up recommendations reflects a lack of research evidence, and a systematic review of international guidelines highlighted the need for robust primary research. It also reports that the accuracy of classifying men into indolent versus progressing groups was poor at all examined cut points of PSA or PSA rate of change.
My PSA is rising after surgery. Does treatment start now?
Not automatically, per PDQ. A detectable PSA after radical prostatectomy identifies elevated risk of local failure or metastatic disease, but PDQ notes a substantial proportion of such patients remain clinically free of symptoms for extended periods, and states that biochemical failure on the basis of an elevated or slowly rising PSA alone may not be sufficient to initiate additional treatment.
How useful is PSA doubling time?
It carries more weight than absolute level, within limits. PDQ cites preliminary data from a retrospective cohort of 8,669 patients where a post-treatment PSA doubling time under 3 months fulfilled some criteria as a surrogate endpoint for all-cause and prostate cancer-specific mortality. PDQ adds these observations need independent prospective confirmation, may not apply to patients on hormonal therapy, and that no standardized surrogacy criteria or cut points exist.
Should I have a PSMA PET scan?
The performance depends on what is being asked. For staging pelvic nodes before treatment, a phase III trial of 764 patients found 68Ga-gozetotide PET-CT had 40% sensitivity and 95% specificity against pelvic lymph node dissection. For detecting metastases in high-risk disease it beat conventional imaging, at 85% versus 38% sensitivity. For recurrence with a rising PSA, 18F-piflufolastat had 95.8% sensitivity and 81.9% positive predictive value.
Is intermittent hormone therapy a real option?
Yes, with good evidence. PDQ describes a randomized noninferiority trial of 1,386 men with a rising PSA above 3 ng/mL more than a year after primary or salvage radiation. Median survival was 8.8 years with intermittent versus 9.1 with continuous therapy (hazard ratio 1.02). Men on intermittent therapy received a median of 15.4 months of treatment versus 43.9 months, and scored significantly better on hot flashes, sexual desire, and urinary symptoms.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Turn this topic into questions for your next appointment.
Talk with a trained specialist or navigator
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Fever of 100.4°F (38°C) or higher during chemo, severe pain, or trouble breathing: call your cancer care team right away, day or night. Call 911 for an emergency.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-08-11 what this meansLast updated: 2026-09-29Next planned review: 2028-07-30
Review details and limits
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes, and this is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and then compared with the sources listed on it, looking for statements those sources do not back up. That check is not a sentence-by-sentence record and can miss errors. It is not a medical review, and it does not confirm the page is complete or right for your situation.
High-risk topic — talk to your care team. This topic can involve urgent, individual medical decisions. This page is general education only: it cannot tell you whether your situation is an emergency or what you personally should do. Follow your oncology team's instructions and contact them for individual guidance.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Words to know
Tap any term to see what it means.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes, and this is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and then compared with the sources listed on it, looking for statements those sources do not back up. That check is not a sentence-by-sentence record and can miss errors. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.